Abstract
Background/Objectives: Personalized radiotherapy strategies based on clinical and biological factors associated with individual radiosensitivity are essential for the future advancement of precision radiation oncology. This prospective exploratory study investigated the associations of clinical, treatment-related, and biological factors with acute and late genitourinary (GU) and gastrointestinal (GI) radiotoxicity in patients with localized prostate cancer. The associations between radiation-induced apoptosis of CD4+ and CD8+ T lymphocytes (RILA) and radiation toxicity were also investigated. Methods: A total of 110 patients with localized prostate cancer treated with definitive volumetric modulated arc therapy (VMAT) were prospectively enrolled. CD4+ and CD8+ RILA values were quantified by flow cytometry before radiotherapy. Associations between radiation toxicity, RILA, and clinical variables were analyzed using linear mixed-effects models and exploratory analyses of maximum toxicity grades. Results: Higher maximum acute GU and GI toxicity grades were associated with higher subsequent late toxicity grades in univariable analyses, although the association remained statistically significant in the multivariable analysis only for GU toxicity. In an exploratory subgroup analysis restricted to patients within the combined second and third CD8+ RILA tertiles, higher continuous CD8+ RILA values were associated with lower acute GU toxicity grades (b = −0.151, p = 0.041). This association was not observed in the overall analysis. Longitudinal analyses did not demonstrate significant associations between CD4+ or CD8+ RILA and late GU or GI toxicity. Exploratory analyses of maximum toxicity grades identified nominally significant associations between CD8+ RILA and grade ≥ 2 late GI toxicity (p = 0.040 and p = 0.041), based on only 10 patients with this outcome. Older age (b = 0.572, p = 0.010) and higher body mass index (b = 0.672, p = 0.036) were associated with higher CD8+ RILA values in the multivariable analysis. Conclusions: Higher maximum acute GU toxicity grades were associated with higher late GU toxicity grades. Exploratory findings involving CD8+ RILA and acute GU or late GI toxicity require cautious interpretation and independent validation. The present results do not establish the clinical predictive utility of RILA. Larger prospective multicentre studies incorporating clinical and dosimetric factors and longer follow-up are needed to determine whether RILA provides additional clinically relevant information for assessing individual radiosensitivity in prostate cancer radiotherapy.